Health Care Costs Associated with Hepatitis C: A Longitudinal Cohort Study. (2010)

• Record Type: Journal Article
• Authors: Krajden, Mel; Kuo, Margot; Zagorski, Brandon; Alvarez, Maria; Yu, Amanda; Krahn, Murray
• Is Part Of: Canadian Journal of Gastroenterology. Volume 24:Number 12(2010)
• Page Start: 717
• Page End: 726
• Publication Date: 2010
• DOI: 10.1155/2010/569692
• Languages: English
• ISSNs: 0835-7900

Abstract

Abstract : BACKGROUND: Disease-specific estimates of medical costs are important for health policy decision making. OBJECTIVE: To identify predictors of health care costs associated with hepatitis C virus (HCV) seropositivity across disease phases. METHODS: HCV laboratory tests from the BC Centre for Disease Control were linked to administrative data pertaining to health services and drugs dispensed to estimate costs among case subjects and controls. The case group comprised HCV seropositive individuals (n=20, 001), and the control group comprised single-tested, HCV seronegative persons (n=70, 752) identified between January 1997 and December 2004. Subject observation time was assigned to the three following disease phases: initial phase (after diagnosis), late phase (late-stage liver disease) and predeath phase (12 months before death). Case subjects and controls were matched for age, sex and a propensity score within each phase to determine the net cost attributable to HCV seropositivity, and were adjusted for demographic and clinical factors. RESULTS: Costs increased with disease progression, with hospitalization being the highest cost component in all phases. Initial and late phase net costs (2005 Canadian dollars) were $1, 850 and $6, 000 per patient per year, respectively. Costs among case subjects were driven by age, comorbidities, mental illness, illicit drug use and HIV coinfection. While predeath case subject and control costs were virtually the same, costs were high and case subjects died at a younger age. CONCLUSION: HCV seropositivity is associated with increased medical costs driven by viral sequelae and medicosocial vulnerabilities (ie, mental illness, illicit drug use and HIV coinfection). Cost mitigation and health outcome improvements will require broad-based prevention programming to reduce vulnerabilities and HCV treatment to prevent disease progression, respectively.